Our top pick for
Long-term investors
Protagenix Therapeutics is currently trading as an over-the-counter stock. But the company plans to launche on the New York Stock Exchange (NYSE) soon, which will make it easier for everyday investors to buy in.
What we know about the Protagenic Therapeutics Inc IPO
Protagenic Therapeutics Inc filed a draft registration with the US Securities and Exchange Commission under the ticker symbol PTIX. Not yet an official IPO, it's one of the first steps of taking a private company public.
There's no news yet about how much the stock will cost when it goes public. No date has been set for when the stock will be publicly available. The shares will be available on the Nasdaq Capital Market.
How to buy shares in Protagenic Therapeutics Inc when it goes public
Once Protagenic Therapeutics Inc goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PTIX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
Finder's picks for buying Protagenic Therapeutics Inc when it goes public
How do similar companies perform?
It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. But evaluating the performance of companies like Protagenic Therapeutics Inc can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield. While this list includes a selection of the most well-known and popular stocks, it doesn't include every stock available.
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
More guides on Finder
-
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
-
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for a $100 million IPO.
-
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
-
Zynga stock jumps 49% on Take-Two acquisition
Zynga stock soared 49% on Take-Two acquisition news. Read on for more information.
-
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
-
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
-
Trump SPAC stock jumps 20% as app launch date is set
The SPAC merging with Trump’s media company saw 20% gain in one trading day.
Ask an Expert